mometasone furoate
mometasone furoate: sourced relationships with 1 company · 6 clinical trials tracked · 1 FDA decision.
mometasone furoate evidence translation
What we can confirm
1 FDA record · 6 tracked trials
What it means
What to watch
Prepared research question
How could mometasone furoate → PRGO affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 2 study sponsors
Related indications
Study sponsors
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| PERRIGO Co plc (PRGO) Reported 2022-03-17 · Current development: unknownSource Uses temporarily relieves these symptoms of hay fever or oth… | Approved |
Clinical Trial Registry Records (6)
A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study
Primary endpoint: Incidence of participants with treatment-emergent adverse events (TEAEs) including adverse events of special interest (AESI), and serious adverse events (SAEs)
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
Primary endpoint: Change from baseline in the endoscopic NPS
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
Primary endpoint: Change from baseline in the endoscopic NPS
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps
Primary endpoint: Change from baseline in sinus (maxillary, ethmoid) percent opacification volume assessed by CT scan
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps - The BiRCh Study
Primary endpoint: Change From Baseline to the 28-day Average of Daily Sinus Total Symptom Score (sTSS) at Week 24
A Randomised, Double-blind, Parallel Group PhIII Study to Assess the Clinical Efficacy and Safety of 100 mg SC Mepolizumab as an Add on to Maintenance Treatment in Adults With Severe Bilateral Nasal Polyps - SYNAPSE (StudY in NAsal Polyps Patients to Assess the Safety and Efficacy of Mepolizumab)
Primary endpoint: Change From Baseline in Total Endoscopic Nasal Polyps Score at Week 52
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with mometasone furoate?
mometasone furoate has dated SEC/FDA relationship records for PERRIGO Co plc.
How many clinical trials involve mometasone furoate?
BioSniper tracks 6 clinical trials involving mometasone furoate.
What is mometasone furoate's latest FDA decision?
The most recent tracked FDA decision for mometasone furoate is Approval, dated March 17, 2022.